Last reviewed · How we verify
Albuterol eMDPI DS
Albuterol is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Albuterol is a beta-2 adrenergic agonist that stimulates beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Acute bronchospasm and reversible airway obstruction in asthma, Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction.
At a glance
| Generic name | Albuterol eMDPI DS |
|---|---|
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Beta-2 adrenergic agonist (short-acting bronchodilator) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Albuterol binds to and activates beta-2 adrenergic receptors located on the smooth muscle of airways, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and bronchodilation, rapidly opening constricted airways. The eMDPI DS (electronic Metered Dose Inhaler with Dose Sensing) formulation is a device innovation that delivers albuterol via inhalation with electronic tracking and feedback capabilities.
Approved indications
- Acute bronchospasm and reversible airway obstruction in asthma
- Chronic obstructive pulmonary disease (COPD) with reversible airway obstruction
Common side effects
- Tremor
- Headache
- Nervousness
- Palpitations
- Tachycardia
- Muscle cramps
Key clinical trials
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma (PHASE4)
- Digihaler in Chronic Obstructive Pulmonary Disease (COPD) (NA)
- A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albuterol eMDPI DS CI brief — competitive landscape report
- Albuterol eMDPI DS updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI